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Background
Allogeneic stem cell transplantation is usually considered the only curative treatment option for
patients with advanced or transformed myelodysplastic syndromes in complete remission, but
post-remission chemotherapy and autologous stem cell transplantation are potential alterna-
tives, especially in patients over 45 years old. 
Design and Methods
We evaluated, after intensive anti-leukemic remission-induction chemotherapy, the impact of
the availability of an HLA-identical sibling donor on an intention-to treat basis. Additionally, all
patients without a sibling donor in complete remission after the first consolidation course were
randomized to either autologous peripheral blood stem cell transplantation or a second consol-
idation course consisting of high-dose cytarabine. 
Results
The 4-year survival of the 341 evaluable patients was 28%. After achieving complete remis-
sion, the 4-year survival rates of patients under 55 years old with or without a donor were 54%
and 41%, respectively, with an adjusted hazard ratio of 0.81 (95% confidence interval [95%
CI], 0.49-1.35) for survival and of 0.67 (95% CI, 0.42-1.06) for disease-free survival. In patients
with intermediate/high risk cytogenetic abnormalities the hazard ratio in multivariate analysis
was 0.58 (99% CI, 0.22-1.50) (P=0.14) for survival and 0.46 (99% CI, 0.22-1.50) for disease-free
survival (P=0.03). In contrast, in patients with low risk cytogenetic characteristics the hazard
ratio for survival was 1.17 (99% CI, 0.40-3.42) and that for disease-free survival was 1.02 (99%
CI, 0.40-2.56). The 4-year survival of the 65 patients randomized to autologous peripheral
blood stem cell transplantation or a second consolidation course of high-dose cytarabine was
37% and 27%, respectively. The hazard ratio in multivariate analysis was 1.22 (95% CI, 0.65-
2.27) for survival and 1.02 (95% CI, 0.56-1.85) for disease-free survival.
Conclusions
Patients with a donor and candidates for allogeneic stem cell transplantation in first complete
remission may have a better disease-free survival than those without a donor in case of
myelodysplastic syndromes with intermediate/high-risk cytogenetics. Autologous peripheral
blood stem cell transplantation does not provide longer survival than intensive chemotherapy.
(Eudract number: NCT00002926; http://www.cancer.gov/clinicaltrials/EORTC-06961)
Key words: myelodysplastic syndromes, secondary acute myeloid leukemia, cytogenetic char-
acteristics, allogeneic stem cell transplantation, autologous stem cell transplantation, intensive
chemotherapy.
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Introduction
The evolution of the spectrum of myelodysplastic syn-
dromes (MDS) varies from an indolent course over several
years to rapid progression to acute myeloid leukemia
(AML).1 Since 1982 MDS have been classified according to
French-American-British criteria.2 The International
Prognostic Scoring System (IPSS)3 distinguishes four risk
groups for survival and AML evolution based on cytoge-
netic subgroups, percentage of bone marrow blasts and
number of cytopenias.4 The World Health Organization
proposed a new classification system for MDS in 1997.5
For the minority of patients younger than 60 years with
advanced stages of MDS, allogeneic stem cell transplanta-
tion (SCT) is usually considered the treatment of choice.6-
8 However, the outcome of autologous peripheral blood
SCT for patients lacking a suitable donor, appeared, in
some studies, comparable to that of allogeneic SCT.6,9,10
Moreover, a retrospective study comparing intensive
chemotherapy alone against chemotherapy followed by
transplantation did not show a clear benefit for
chemotherapy followed by SCT.11
This study addressed the issue of whether the existence
of an HLA-identical sibling donor and the intention to per-
form an allogeneic SCT after the first consolidation course
of chemotherapy results in a favorable outcome. The main
aim of this study was to compare prospectively the value
of autologous peripheral blood SCT with a second consol-
idation course. Finally the study assessed the impact of
cytogenetic characteristics, including those determined by
fluorescence in situ hybridization (FISH) studies, on out-
come. 
Design and Methods
Patients and investigations
Patients seen between November 1996 and September 2003
were included in this study if they met the following selection cri-
teria: MDS with more than 10% bone marrow blasts, other forms
of MDS with multiple chromosomal abnormalities and/or pro-
found cytopenias (defined as a neutrophil count <0.5¥109/L and/or
platelet count <20¥109/L), chronic myelomonocytic leukemia with
more than 5% bone marrow blasts, chronic myelomonocytic
leukemia with more than 16¥109/L neutrophils or 2.6¥109/L
monocytes in the blood, and MDS transformed to AML after a
documented MDS lasting 6 months or longer. Patients who had
already received intensive chemotherapy and/or radiotherapy for
their MDS or AML were not eligible. Patients treated with biolog-
ical response modifiers and/or low-dose cytarabine in the 4 weeks
preceding potential inclusion in this study were not eligible for the
study (further details of inclusion and exclusion criteria and labo-
ratory investigations, including FISH analyses, are given in the
Online Supplementary Appendix). 
This study was approved by the ethics committees of the par-
ticipating institutions and was conducted in accordance with the
Declaration of Helsinki. All participants gave their informed con-
sent.
Study design 
The Criant study was a randomized, phase 3 intergroup study
carried out by the European Organization for Research and
Treatment of Cancer (EORTC) Leukemia Group, the Gruppo
Italiano Malattie Ematologiche dell’Adulto (GIMEMA), the Dutch-
Belgian Haemato-Oncology Cooperative group (HOVON), the
Swiss Group for Clinical Cancer Research (SAKK), the European
Blood and Marrow Transplantation (EBMT) group and the Nordic
MDS group in 39 European centers. The design of the study and
the disposition of patients are illustrated in Figure 1.
Remission-induction chemotherapy consisted of idarubicin 10
mg/m2 on days 1, 3, and 5, cytarabine 100 mg/m2, as a continuous
intravenous infusion, on days 1-10, and etoposide 100 mg/m2,
intravenously, on days 1-5 (ICE), followed by a second identical
remission-induction course in the case of a partial remission. The
availability of histocompatible sibling donors was evaluated for
patients who achieved a complete remission. 
After achieving complete remission, a course of consolidation
therapy was given which consisted of idarubicin 10 mg/m2 admin-
istered intravenously on days 4-6 in combination with cytarabine
500 mg/m2 12-hourly in a 2-hour intravenous infusion on days 1-
6 (IDIA). Patients aged 55 years or less (but also some who were
older, according to the policy of each center) with an identified
HLA-A, -B, -DR identical sibling, non-reactive mixed lymphocyte
culture and confirmed complete remission after the course of con-
solidation chemotherapy were offered allografting. Patients with-
out a donor received 300 mg granulocyte colony-stimulating factor
subcutaneously daily from day 20 after the start of the consolida-
tion course until completion of mobilization. Patients without a
donor and in complete remission after the consolidation course
were randomized between a second consolidation course consist-
ing of cytarabine 1 g/m2 intravenously, every 12 h, on days 1-6 and
autologous peripheral blood SCT. The randomization did not
depend on the quality of the stem cell harvest during the first
mobilization procedure. Patients with an insufficient harvest and
randomized for autologous SCT were candidates for a second
attempt at stem cell mobilization with granulocyte colony-stimu-
lating factor only. Details of the transplantation regimens and def-
initions are given in the Online Supplementary Appendix.
Statistical analysis
All patients were registered prospectively at the EORTC Data
Center in Brussels. Randomization (autologous peripheral blood
SCT versus high-dose cytarabine) was stratified for center and
various other factors (for details, see the Online Supplementary
Appendix. The duration of survival was calculated from the date
of the start of treatment until death, irrespective of the cause. For
patients who achieved complete remission after induction, the
disease-free survival was calculated from the date of first com-
plete remission until the date of first relapse or until death in
complete remission. The duration of survival of patients who
achieved a complete remission was taken to be the time from
the first complete remission to the date of death. For patients
randomized, the starting point for disease-free survival and
other survival analyses was the date of randomization. The
Kaplan-Meier technique was used to estimate survival-type dis-
tributions and the standard errors (SE) of the estimates were
obtained using Greenwood’s formula. The estimates of the inci-
dence of relapse and of death in complete remission were
obtained using the competing risk method. A Cox proportional
hazard model was used to determine the prognostic importance
of several factors and to obtain estimates of the hazard ratio
(HR) and the corresponding 95% confidence interval (CI) or
99% CI, in the case of subgroup analysis. Analyses were per-
formed according to the intention-to-treat principle. However,
patients who did not reach complete remission or who relapsed
before randomization were excluded from the disease-free sur-
vival and survival from randomization analyses. For the compar-
isons of disease-free survival and overall survival in patients
younger than 55 years who did or did not have a donor, the sur-
vival times were measured from the time at which the patient
Intensive antileukemic therapy in MDS and sAML 
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achieved complete remission. This means that patients who did
not receive a consolidation course were included in this analysis
as well.
Power calculations
In the initial protocol it was planned to randomize a total of 100
patients, of whom 80 were required to be followed until relapse or
death, in order to detect a 20% difference (10% versus 30%) in the
2-year disease-free survival rates between the two treatment
groups, corresponding to a hazard ratio of 0.52 (logrank 2 tailed
test, alpha error=0.05) with an 80% statistical power. During the
study period, only 65 patients could be randomized, of whom 49
relapsed or died in complete remission, providing a 60% statistical
power for the detection of a treatment difference regarding dis-
ease-free survival.
Results
Patients’ characteristics
A total of 345 patients were registered, of whom 341
were evaluable for response (Figure 1). Reasons for exclu-
sion were treatment refusal, wrong diagnosis, World
Health Organization performance status greater than 2,
and missing data. The characteristics of the 341 evaluable
patients are summarized in Table 1. Their median age was
51 years (range, 16-67 years). According to the French-
American-British criteria 7 patients had refractory anemia,
2 patients had refractory anemia with ring sideroblasts,
104 patients had refractory anemia with excess of blasts,
131 patients had refractory anemia with excess of blasts in
transformation, 20 patients had chronic monomyelocytic
leukemia, and 77 patients had secondary AML. Twenty-
two patients were classified in the intermediate-1 risk
group according to IPSS; the remaining patients had a
higher risk score reflecting the advanced disease stage of
most patients. Reviewed cytogenetic data were available
for 295 (86%) patients and FISH data for 158 patients
(46%).
Remission-induction and consolidation therapy
The median follow-up of the 341 evaluable patients was
5.3 years and 256 patients have died. Complete remission
was achieved in 173 patients after one course of treatment
and in 194 patients (57%) after one or two courses. The
remaining patients had either resistant disease, persistent
hyperplasia or died before hematopoietic recovery (Figure
1). The first consolidation course was administered to 175
of the 194 patients who achieved a complete remission
(Figure 1). The median survival in these patients was 1.3
years (95% CI, 1.0 - 1.7 years) and the 4-year survival rate
was 28% (SE=2.5%) (Figure 2). The median disease-free
survival was 1.0 year and the 4-year disease-free survival
rate was 29%. The 4-year cumulative incidence of relapse
was 60% and that of death in complete remission, 11%.
Fifty-three patients (27%) continued to be alive in contin-
uous complete remission. 
Prognostic factors influencing survival
Age influenced the treatment outcome significantly
(P=0.0001): the 4-year survival rate was 43% for patients
younger than 46 years, 25% for those 46 to 55 years old
and 19% for those older than 55 years. The percentage of
bone marrow blasts did not influence outcome (Online
Supplementary Table S1). The number of cytopenias was of
prognostic importance for survival (P=0.02) mainly due to
the poor outcome of patients with trilineage cytopenia.
Disease duration longer than 6 months prior to inclusion
in the study was associated with a significantly (P=0.009)
lower 4-year survival rate: 13% (SE=5%) versus 30%
(SE=3%) for patients whose disease had been present for
a shorter time. The white blood cell count also influenced
survival (overall P=0.02) mainly due to a negative impact
of counts higher than 25¥109/L.
Cytogenetic characteristics were the most significant
(P<0.0001) disease-associated prognostic factor. The 4-
year survival rate of the 127 patients with good-risk cyto-
genetic features was 44%, while the survival rates of the
intermediate- and high-risk groups were 28% and 9%,
respectively. The IPSS risk group was not of prognostic
importance for survival, mainly due to the high weight of
bone marrow blast percentage in this model (Online
Supplementary Table S1).
Multivariate analysis showed that age (> 45 years versus
≤ 45 years: HR, 1.8; 95% CI, 1.3 to 2.4) and IPSS cytoge-
netic risk group (intermediate versus good: HR, 1.8; 95%
T. De Witte et al.
1756 haematologica | 2010; 95(10)
Table 1. Characteristics of total study group, of the donor and no-donor
groups* and of the groups randomized between autologous peripheral
blood stem cell transplantation (APSCT) and chemotherapy.
Variable                 Number of   Donor   No-donor  APSCT Chemotherapy
                         patients (%)   group      group
Total number of pts.     341               50               85             31                 34
Age (years)                                                                                                      
≤ 40                             71 (21)        17 (34)       24 (28)       5 (16)          7 (21)
41-45                             32 (9)        11 (22)       10 (12)         2 (6)            1 (3)
46-55                         133 (39)        22 (44)       51 (60)    11 (36)        16 (47)
> 55                          105 (31)                  –                  –     13 (42)        10 (29)
Bone marrow blasts (%)&
< 5                               15 ( 4)            0 (0)           3 (4)         0 (0)            1 (3)
5-9                               33 (10)            4 (8)       22 (26)         2 (6)          9 (26)
10-19                         114 (33)        24 (48)       28 (33)    14 (45)        12 (35)
20-29                           84 (25)        16 (32)      14 ( 17)       4 (13)          9 (27)
≥30#                             66 (19)          5 (10)       11 (13)       8 (26)            2 (6)
Missing (dry tap)      29 (9)            1 (2)           7 (8)         4 (9)            1 (3)
IPSS cytogenetic risk groups##
Good**                    127 (37)        22 (44)       37 (44)    24 (71)        16 (42)
Intermediate            63 (19)        11 (22)       13 (15)         2 (6)          4 (11)
Poor***                   107 (31)        11 (22)       21 (25)       5 (15)        12 (32)
Missing                      44 (13)          6 (12)       14 (17)         3 (9)          6 (16)
Disease duration prior to treatment
<6 months              286 (84)        45 (90)       80 (94)    29 (85)        36 (95)
≥6 months                 46 (13)            3 (6)           3 (4)       4 (12)            2 (5)
Number of cytopenias                                                                                             
0-2                             200 (58)        35 (70)       48 (56)    14 (41)        26 (68)
3                                 141 (41)        15 (30)       37 (44)    20 (59)        12 (32)
White blood cell count (¥109/L)
<25                           304 (89)        46 (92)       81 (95)    31 (91)        34 (90)
≥25                              37 (11)            4 (8)           4 (5)         3 (9)          4 (10)
*Donor versus no-group comparison restricted to patients < 55 years, in complete
remission after remission-induction; &some discrepancies between the French-
American-British classification and the percentage of bone marrow blasts can be
explained by the definition of refractory anemia with excess blasts in trasformation
which includes patients with >5% peripheral blood blasts and by the inclusion of the
marrow biopsy data in case of a dry tap; #secondary AML after documented MDS last-
ing 6 months or longer; ##conventional banding and FISH; **normal metaphases (≥11
mitoses) or –Y, 5q- or 20q- only, or t(8;21) or inv(16) without poor cytogenetic features;
***presence of -7 or 7q- or -5 or complex abnormalities (≥3 abnormalities). 
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CI, 1.2-2.6; poor versus good: HR, 3.2; 95% CI, 2.4-4.5)
were the most important independent prognostic vari-
ables for duration of survival. Prolonged disease duration
(≥ 6 months), high white blood cell count (> 25¥109/L) and
trilineage cytopenia were additional independent features
associated with a shorter survival, with P values of 0.004,
0.005, and 0.02, respectively.
Post-remission therapy: donor versus no donor
The policy of performing HLA-typing of patients and
their siblings was age-dependent. An HLA-identical sib-
ling was identified in 50 of the 135 patients younger than
56 years (37%) compared to only 8 of the 55 patients older
than 55 years (15%). The comparison of the treatment
outcome of patients with or without a donor was, there-
fore, restricted to patients younger than 56 years (Figure
1). Among the 50 patients with a donor, 47 received the
planned allogeneic SCT, including four patients who
received the transplant after progression of their disease.
The median time from complete remission to allogeneic
SCT in the 44 patients who received the allogeneic SCT in
first complete remission was 3 months (range, 0 to 8
months). Details of the transplant procedures are present-
ed in the Online Supplementary Appendix.
The 85 patients without a donor received autologous
peripheral blood SCT (13 patients), high-dose chemother-
apy only (63 patients) or allogeneic SCT from alternative
donors (9 patients). The median time from complete
remission to autologous SCT or high-dose cytarabine
chemotherapy was 3 months (range, 2 to 19 months).
Eight patients underwent allogeneic SCT from an alter-
native donor after progression of their disease. The 4-year
disease-free survival rates of patients with or without a
donor were 46% and 27%, respectively (HR, 0.63; 95%
CI, 0.41 - 0.99) (Table 2; Figure 3). The 4-year relapse inci-
Intensive antileukemic therapy in MDS and sAML 
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Figure 1. Overview of treatment
allocation of all 341 eligible
patients.*Reasons for not admin-
istering the scheduled consolida-
tion course were: early relapse
(n=2), protocol violation (n=4),
toxicity (n=10), refusal (n=1), and
other reasons (n=2). Seven of
these patients had an HLA-identi-
cal sibling and five of them
received an allograft in first com-
plete remission without the con-
solidation course. **Reasons for
not randomizing the patients
were: early relapse (n=11), toxicity
(n=11), refusal (n=3), protocol vio-
lation (n=3), allograft (n=1), auto-
graft (n=3), ineligibility for ran-
domization (n=2), other (n=5) #:
In total 68 patients were random-
ized (including 42 patients
younger than 55 years who partic-
ipated in the donor versus no
donor comparison), but three
patients were considered ineligi-
ble because they had relapsed
before randomization. CR: com-
plete remission; CR-1: first com-
plete remission; AlloSCT: allo-
geneic stem cell transplantation;
APSCT: autologous peripheral
blood stem cell transplantation.
After progression
8 Alt. alloSCT
2 APSCT
After progression
4 AlloSCT25 performed Cons-216 performed APSCT
31 APSCT
19 successful harvest
34 consolidation-2
14 successful harvest
65 randomized#39 non randomized** Treatment in CR-1
42 randomized#
9 alt. allo SCT
63 chemo only
13 APSCT
Treatment in CR-1
43 AlloSCT
50 donor 85 no donor
135 age < 55 years
17 mobilization unknown107 mobilization
175 consolidation-1
all ages
19 no consolidation-1*
all ages
51 donor
147 no CR 194 CR
341 evaluable patients
Table 2. Comparison of patients with and without a donor who reached com-
plete remission and were ≤ 55 years old, regarding disease-free survival (DFS)
and overall survival (OS) from complete remission.
DFS OS
                                                Donor           No donor            Donor         No donor
All patients#                                     29/50                  63/85                    25/50                53/85
4-year rate (SE)*                         46 (7)                27 (5)                  54 (7)             41 (6)
HR (95%CI) (**;1) 0.63 (0.41-0.99) 0.75 (0.46-1.20)
P value(**;1) 0.04 0.23
HR (95%CI) (**;2) 0.67 (0.42-1.06) 0.81 (0.49-1.35)
P value(**;2) 0.09 0.41
IPSS cytogenetic group                13/22                  24/37                    10/22                18/37
low risk#                                                
4-year rate (SE)*                        50 (11)               38 (8)                 64 (10)             61 (8)
HR (99%CI) (**;1) 0.83 (0.34-2.02) 0.98 (0.35-2.70)
P value(**;1) 0.58 0.95
HR (99%CI) (**;3) 1.02 (0.40-2.56) 1.17 (0.40-3.42)
P value(**;3) 0.96 0.71
IPSS cytogenetic group                13/22                  30/34                    12/22                28/34
intermediate/high risk#
4-year rate (SE)*                        40 (11)               11 (6)                 45 (11)             15 (7)
HR (99%CI) (**;1) 0.43 (0.18-1.02) 0.50 (0.20-1.22)
P value(**;1) 0.01 0.04
HR (99%CI) (**;4) 0.46 (0.19-1.13) 0.58 (0.22-1.50)
P value(**;4) 0.03 0.14
#Each row gives the observed number of events/number of patients; *Kaplan-Meier estimates
along with standard error (SE) obtained with the Greenwood formula; **P value given by the
Wald test (via a Cox model); (1): univariate analysis (2): multivariate analysis (Cox model): com-
parison adjusted for age  (≤ 45 versus 46-55), IPSS cytogenetics/FISH (low versus intermediate
versus poor versus unknown) and number of cytopenias (0-2 versus 3); (3): multivariate analysis
(Cox model): comparison adjusted for age (≤ 45 versus 46-55) and number of cytopenias (0-2
versus 3); (4): multivariate analysis (Cox model): comparison adjusted for age (<= 45 versus 46-
55), IPSS cytogenetics/FISH (intermediate versus poor) and number of cytopenias (0-2 versus 3);
HR: hazard ratio donor versus no donor.
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dence in patients with a donor was 41% whereas it was
64% in the group without donors (P=0.008); the cumula-
tive incidences of death in complete remission were 14%
and 10%, respectively (P=0.38). The 4-year survival rates
in the two groups were 54% and 41% respectively (HR,
0.75, 95% CI, 0.46 to 1.20) (Table 2). The median time
from complete remission to transplantation of the nine
patients transplanted with grafts from alternative donors
was 3.8 months (range, 2.5-6.2 months). Three patients
died in complete remission and six remained in complete
remission (range, 2.6-6.6 years). By censoring their follow-
up at the time of the allogeneic SCT, the comparison of
disease-free survival in patients with or without donors,
adjusted for age, cytogenetics/FISH and number of
cytopenias, yielded similar results (HR, 0.62; 95% CI,
0.39-0.99).
According to a multivariate Cox model (Table 2), the
existence of a donor resulted in a better disease-free sur-
vival: the ‘donor’ versus ‘no donor’ comparison yielded a
HR of 0.67 (95% CI, 0.42-1.06). The HR ratio for survival
was, however,  close to 1 (0.81; 95% CI, 0.49-1.35). In this
model, the test for an interaction ‘donor availability’ –
‘cytogenetic risk group’ was of borderline statistical signif-
icance (P=0.10) with regards to disease-free survival, indi-
cating that some heterogeneity may exist according to the
cytogenetic group regarding the differences in outcome
between patients with or without a donor. In the low risk
cytogenetic group (59 patients) the ‘donor’ versus ‘no
donor’ comparison yielded a HR of 1.02 (99% CI, 0.40-
2.56). In contrast, in the group with intermediate or poor
cytogenetic characteristics (56 patients), the ‘donor’ versus
‘no donor’ comparison yielded a HR for disease-free sur-
vival of 0.46 (99% CI, 0.19-1.13) (Table 2) and for duration
of survival a HR of 0.58 (99% CI, 0.22-1.50).
Mobilization of stem cells, stem cell harvest 
and post-consolidation randomization
Mobilization of stem cells during the recovery phase
after the first consolidation course was adequate in 48
patients and failed in 61 patients. In total 65 patients in
complete remission were randomized: 31 to autologous
peripheral blood SCT and 34 to a second consolidation
course (high-dose cytarabine) (Figure 1). Forty-two of the
randomized patients were younger than 56 years and 23
patients were older than 55 years. The relevant character-
istics are presented in Table 1. The reasons for not ran-
domizing the 39 patients are indicated in Figure 1. The
normal treatment completion rate was 52% (16/31) and
74% (25/34) in the autologous and high-dose cytarabine
groups, respectively. In the autologous SCT arm 12
patients did not receive the planned transplant because of
an inadequate harvest of stem cells and four patients
because of toxicity. In the high-dose cytarabine group two
patients did not receive the second consolidation course
due to toxicity, two patients due to protocol violation (one
underwent allogeneic SCT from an alternative donor and
one underwent autologous SCT) and five patients due to
early relapse. Out of the 65 randomized patients, 47
relapsed (20 autologous SCT, 27 high-dose cytarabine) and
two patients died in complete remission after autologous
SCT. The 4-year disease-free survival rates in the autolo-
gous SCT and high-dose cytarabine groups were 29% and
T. De Witte et al.
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Figure 2. Survival from registration in study, for all patients, and sur-
vival from complete remission for all patients who reached complete
remission. 
Figure 3. Survival from complete remission without relapse accord-
ing to the availability of a HLA identical sibling in patients ≤55 years
old.
Table 3. Comparison of patients randomized between autologous
peripheral blood stem cell transplantation and a second consolida-
tion course with high-dose cytarabine, regarding disease-free survival
and overall survival from randomization.
DFS OS
APSCT HDAC APSCT HDAC
Number of patients 31 34 31 34
4-year rate (SE)* 27 (8) 22 (7) 37 (9) 27 (8)
HR (95% CI) (**;1) 0.78 (0.44 , 1.37) 0.89 (0.49 , 1.61)
P value (**;1) 0.38 0.71
HR (95% CI) (**;2) 1.02 (0.56 , 1.85) 1.22 (0.65, 2.27)
P value (**;2) 0.95 0.55
*Kaplan-Meier estimates along with standard error (SE) obtained with the Greenwood
formula; **P value given by the Wald test (via a Cox model); (1): univariate analysis
(2): multivariate analysis (Cox model): comparison adjusted for age (≤ 45 versus 46-
55), IPSS cytogenetics/FISH (low versus intermediate versus poor versus unknown)
and number of cytopenias (0-2 versus 3); HR = hazard ratio APSCT versus HDAC.
APSCT: autologous peripheral blood stem cell transplantation; HDAC: high-dose
cytarabine; DFS: disease-free survival; OS: overall survival.
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19%, respectively (Table 3 and Figure 4). Several differ-
ences were identified between the two groups: in the
autologous SCT group more patients were older than 55
years and fewer patients had poor-risk cytogenetic charac-
teristics (Table 1). The estimated HR for autologous SCT
versus high-dose cytarabine was 0.98 (95% CI, 0.56-1.86)
after adjustment of disease-free survival for these two fac-
tors. The 4-year survival rate of the two groups was 37%
and 27%, respectively (P=0.71) (Table 3 and Figure 4). The
treatment comparison adjusted for age and cytogenetics
yielded a HR of 1.22 (95% CI, 0.65 to 2.29).
Discussion
The results of intensive chemotherapy in patients with
advanced stages of MDS have improved with complete
remission rates now ranging between 44% and 64%,12-17
similar to the 57% complete remission rate observed in
this study. Remission after chemotherapy usually lasts less
than 12 months.14,17 Chromosomal characteristics are
important prognostic factors influencing remission dura-
tion.13 The percentage of patients with poor-risk cytoge-
netic characteristics in this study was high (31%) com-
pared to the observed 10% poor-risk patients in large
AML studies.18,19 The 9% 4-year survival rate of patients
with poor-risk cytogenetic characteristics in this study
was low compared to 4-year survival rates of patients
with good risk (44%) or intermediate risk characteristics
(28%). The IPSS did not influence the outcome in this
study due to the lack of impact of the percentage of bone
marrow blasts which constitutes an important factor in
this score.3 The patient’s age influenced the outcome sig-
nificantly, irrespective of the post-remission therapy
modality. The overall 4-year survival rate was 43% in
patients younger than 45 years compared to only 19% for
those older than 55 years. 
In view of the high relapse rate after chemotherapy
alone, transplantation with autologous stem cells has been
applied with the aim of intensifying post-remission thera-
py.20-22 In a previous study by our group, we analyzed 100
patients in first complete remission who were candidates
for SCT.9,23 The 4-year disease-free survival rates in the
donor versus no-donor groups were similar: 31% and 27%,
respectively. This outcome suggests that patients with
advanced stages of MDS may benefit both from allogeneic
and from autologous SCT. In our present study the 46% 4-
year disease-free survival rate in the group of patients with
donors was considerably higher than that in the previous
study. This may reflect the generally better transplant
results in more recently performed SCT.6 In the present
study the non-relapse mortality was only 14% in the
donor-group compared to 27% in the previous study.9,23
Subgroup analysis of this study showed that the advan-
tage of the presence of a donor was only apparent in the
group of patients with intermediate and high risk cytoge-
netics (table 3). This observation is in line with the previ-
ous study9 which showed only long-term survivors after
autologous SCT in patients with good-risk characteris-
tics.24 The overall survival in the donor group was not sig-
nificantly superior to that in the no-donor group, although
in patients with intermediate and high-risk cytogenetic
characteristics a trend to a superior survival in the donor
group was observed (HR, 0.58; 99% CI, 0.22–1.50;
P=0.14). However, the disease-free survival was signifi-
cantly superior in the donor-group with intermediate and
poor risk characteristics (HR, 0.46; 99% CI, 0.19-1.13;
P=0.03). Salvage therapy after relapse may have con-
tributed to the improved overall survival from complete
remission in the no-donor group. Thirteen patients under-
went allogeneic SCT after relapse and five patients in the
no-donor group are still alive with a median follow-up of
4.1 years after relapse. Several large studies of patients
with de novo AML have addressed the prognostic impact
of a histocompatible sibling donor.19,25,26 In these studies
the advantage of the existence of such a donor was mainly
restricted to patients younger than 40 years. In our study
group the average age was considerably higher and only
28% (38/135) of the patients who reached complete
remission and were 55 years or younger, were actually
under 40 years old. This small number precludes a sepa-
rate analysis in the young age group. The results in de novo
AML are in line with our own observations. Usually
patients with unfavorable or intermediate cytogenetic
characteristics appear to benefit from allogeneic SCT. 
Polyclonal primitive hematopoietic progenitors can be
mobilized in patients with MDS after treatment with
intensive chemotherapy.27 The present study shows that
stem cell mobilization was feasible in a minority (45%) of
the patients. This relatively low yield of a sufficient num-
ber of stem cells may reflect the low number of residual
normal stem cells after chemotherapy or damage to the
bone marrow stroma caused by pro-apoptotic cytokines
produced by the MDS clone.28 The prolonged hypoplasia
after the first consolidation course interfered with the
number of randomized patients since the randomization
was planned after hematopoietic recovery from this con-
solidation course. Only 65 of the 107 candidates were ran-
domized between autologous SCT and the second consol-
idation course. The outcome of the two groups after
adjustment for the most important confounding factors
was identical. It is clear that better mobilization schedules
should be developed before autologous peripheral blood
SCT can be recommended as part of the intensive post-
remission treatment protocols of MDS patients. New
prospective studies will be necessary when better mobiliz-
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Figure 4 . Survival (two upper curves) and disease-free survival (two
lower curves) from randomization according to the randomization
group. N: number of patients; O: observed number of events (death –
for survival analysis –, or relapse or death without relapse); P value
given by the logrank test. APSCT: autologous peripheral blood stem
cell transplantation; HDAC: high-dose cytarabine.
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ing schedules for MDS have been identified.
Whether patients with advanced stages of MDS should
receive remission-induction chemotherapy prior to the
transplant conditioning remains a point for discussion.
Retrospective analyses provided conflicting data and inter-
pretation of the data is hampered by various selection bias-
es in the two treatment approaches and by a lack of detail
on the chemotherapy administered.6,29 This study shows
that the great majority of patients with an identified donor
received the transplant (94%). The 4-year disease-free sur-
vival rate of 46% among the group with a donor is encour-
aging compared to results from a large registry.30
In conclusion, our data suggest that allogeneic SCT may
be the treatment of choice for the young patients (age ≤55
years) with MDS, characterized by poor risk or intermedi-
ate risk cytogenetics, who have a histocompatible donor.
For MDS patients lacking an HLA-compatible sibling
donor, but with good-risk cytogenetic characteristics, autol-
ogous SCT or chemotherapy may be good alternatives. 
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